Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

The binding characteristics and orientation of a novel radioligand with distinct properties at 5-HT3A and 5-HT3AB receptors.

Thompson AJ, Verheij MH, Verbeek J, Windhorst AD, de Esch IJ, Lummis SC.

Neuropharmacology. 2014 Nov;86:378-88. doi: 10.1016/j.neuropharm.2014.08.008. Epub 2014 Aug 28.

2.

A single channel mutation alters agonist efficacy at 5-HT3A and 5-HT3AB receptors.

Thompson AJ, Lummis SC.

Br J Pharmacol. 2013 Sep;170(2):391-402. doi: 10.1111/bph.12287.

3.

Structure-activity relationships of quinoxaline-based 5-HT3A and 5-HT3AB receptor-selective ligands.

Thompson AJ, Verheij MH, van Muijlwijk-Koezen JE, Lummis SC, Leurs R, de Esch IJ.

ChemMedChem. 2013 Jun;8(6):946-55. doi: 10.1002/cmdc.201300032. Epub 2013 May 2.

4.

VUF10166, a novel compound with differing activities at 5-HT₃A and 5-HT₃AB receptors.

Thompson AJ, Verheij MH, de Esch IJ, Lummis SC.

J Pharmacol Exp Ther. 2012 May;341(2):350-9. doi: 10.1124/jpet.111.190769. Epub 2012 Feb 3.

5.
6.

The binding orientations of structurally-related ligands can differ; A cautionary note.

Ruepp MD, Wei H, Leuenberger M, Lochner M, Thompson AJ.

Neuropharmacology. 2017 Jun;119:48-61. doi: 10.1016/j.neuropharm.2017.01.023. Epub 2017 Jan 27.

7.

The loop C region of the murine 5-HT3A receptor contributes to the differential actions of 5-hydroxytryptamine and m-chlorophenylbiguanide.

Suryanarayanan A, Joshi PR, Bikádi Z, Mani M, Kulkarni TR, Gaines C, Schulte MK.

Biochemistry. 2005 Jun 28;44(25):9140-9.

PMID:
15966738
8.

Agonists and antagonists induce different palonosetron dissociation rates in 5-HT₃A and 5-HT₃AB receptors.

Lummis SC, Thompson AJ.

Neuropharmacology. 2013 Oct;73:241-6. doi: 10.1016/j.neuropharm.2013.05.010. Epub 2013 Jun 5.

9.

Agonists and antagonists bind to an A-A interface in the heteromeric 5-HT3AB receptor.

Lochner M, Lummis SC.

Biophys J. 2010 Apr 21;98(8):1494-502. doi: 10.1016/j.bpj.2009.12.4313.

10.

Characterizing new fluorescent tools for studying 5-HT₃ receptor pharmacology.

Jack T, Simonin J, Ruepp MD, Thompson AJ, Gertsch J, Lochner M.

Neuropharmacology. 2015 Mar;90:63-73. doi: 10.1016/j.neuropharm.2014.11.007. Epub 2014 Nov 22.

PMID:
25460187
11.

Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.

Del Cadia M, De Rienzo F, Weston DA, Thompson AJ, Menziani MC, Lummis SC.

Bioorg Med Chem. 2013 Dec 1;21(23):7523-8. doi: 10.1016/j.bmc.2013.09.028. Epub 2013 Sep 20.

12.

Pharmacological and electrophysiological properties of the naturally occurring Pro391Arg variant of the human 5-HT3A receptor.

Kurzwelly D, Barann M, Kostanian A, Combrink S, Bönisch H, Göthert M, Brüss M.

Pharmacogenetics. 2004 Mar;14(3):165-72.

PMID:
15167704
13.

Characterization of [3H]meta-chlorophenylbiguanide binding to 5-HT3 receptors in N1E-115 neuroblastoma cells.

Lummis SC, Sepúlveda MI, Kilpatrick GJ, Baker J.

Eur J Pharmacol. 1993 Oct 12;243(1):7-11.

PMID:
8253126
14.

Importance of the C-terminus of the human 5-HT3A receptor subunit.

Butler AS, Lindesay SA, Dover TJ, Kennedy MD, Patchell VB, Levine BA, Hope AG, Barnes NM.

Neuropharmacology. 2009 Jan;56(1):292-302. doi: 10.1016/j.neuropharm.2008.08.017. Epub 2008 Aug 22.

PMID:
18786552
15.

Locating an antagonist in the 5-HT3 receptor binding site using modeling and radioligand binding.

Thompson AJ, Price KL, Reeves DC, Chan SL, Chau PL, Lummis SC.

J Biol Chem. 2005 May 27;280(21):20476-82. Epub 2005 Mar 21.

16.

Varenicline is a potent agonist of the human 5-hydroxytryptamine3 receptor.

Lummis SC, Thompson AJ, Bencherif M, Lester HA.

J Pharmacol Exp Ther. 2011 Oct;339(1):125-31. doi: 10.1124/jpet.111.185306. Epub 2011 Jul 20.

17.

Subtle Differences among 5-HT3AC, 5-HT3AD, and 5-HT3AE Receptors Are Revealed by Partial Agonists.

Price KL, Hirayama Y, Lummis SCR.

ACS Chem Neurosci. 2017 May 17;8(5):1085-1091. doi: 10.1021/acschemneuro.6b00416. Epub 2017 Apr 3.

PMID:
28367632
18.

The muscarinic antagonists scopolamine and atropine are competitive antagonists at 5-HT3 receptors.

Lochner M, Thompson AJ.

Neuropharmacology. 2016 Sep;108:220-8. doi: 10.1016/j.neuropharm.2016.04.027. Epub 2016 Apr 22.

19.

Characterization of the ligand-binding site of the serotonin 5-HT3 receptor: the role of glutamate residues 97, 224, AND 235.

Schreiter C, Hovius R, Costioli M, Pick H, Kellenberger S, Schild L, Vogel H.

J Biol Chem. 2003 Jun 20;278(25):22709-16. Epub 2003 Mar 26.

20.

Allosteric activation of the 5-HT3AB receptor by mCPBG.

Miles TF, Lester HA, Dougherty DA.

Neuropharmacology. 2015 Apr;91:103-8. doi: 10.1016/j.neuropharm.2014.12.018. Epub 2014 Dec 23.

Supplemental Content

Support Center